SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TME Pharma GLORIA Team Wins 2026 German University Medicine Prize

The GLORIA study team received the prize. In a six-patient expansion cohort, NOX-A12 plus radiotherapy and bevacizumab was well tolerated, with median overall survival of 19.9 months; no comparison was provided.

ALTME
SquawkNews Desk

Related stories

Pfizer Reports Q3 Revenue of $16.6 Billion, Raises 2026 Guidance Pfizer reported third-quarter 2026 revenue of $16.6 billion, relatively flat year over year operationally, and adjusted diluted EPS of $0.87. It raised full-year revenue guidance t M impact | EQUITY | Nov 03, 2026, 01:22 PM UTC CACI Wins Five-Year, $108 Million U.S. Air Force Contract CACI said it was awarded a five-year, $108 million contract by the U.S. Air Force to advance financial transparency, operational efficiency and mission readiness. M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC Petrobras shares fall more than 3% in early trading M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC Teva Q3 Revenue Falls 2% to $4.4 Billion, Raises 2026 Brand Outlook Teva reported third-quarter 2026 revenue of $4.395 billion, down 2% year over year. Gross margin was 55.5%, net income attributable to Teva was $233 million and adjusted diluted EP M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC Chegg Q3 Revenue Falls as Legacy Business Declines M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC Madrigal Reports Third-Quarter Revenue of $431.3 Million and Net Income of $55.4 Million Madrigal reported third-quarter 2026 revenue up 50% year over year. Diluted earnings were $1.83 per share, compared with a loss of $4.01 per share a year earlier. M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC